paroxetine is a Medicine belongs to Antidepressant Agents group whose information about Brand can be referenced from   Book : Martindale    Page : 441,442   Edition : 38  

  ►   Brandname : Cinpar-CR, Deprox, Leparox, Brisdelle, Seroxat, Aropax, Paroxalon, Le You, Paxil
  ►  Strength : Tablet with 10 mg.  Tablet with 20 mg.  Tablet with 30 mg.  Tablet with 40 mg.  Suspension with 10 mg/5mL.  Controlled-release tablets with 12.5 mg.  Controlled-release tablets with 25 mg.  Controlled-release tablets with 37.5 mg. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 539   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 441   Edition : 38  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Depression Oral 20 mg Tablet The doses are given daily, increased gradually, if necessary, to a maximum of 50 mg daily.
2 Generalised anxiety disorder Oral 20 50 mg Tablet Does given daily.
3 Obsessive-compulsive disorder Oral 20 mg Tablet Dose may be increased gradually to a usual maintenance dose of 40 mg daily; some patients may require up to 60 mg daily.
4 Panic disorder with or without agoraphobia Oral 10 mg Tablet Dose may be increased gradually to a usual recommended maintenance dose is 40 mg daily, although some patients may benefit from 60 mg daily.
5 Post-traumatic stress disorder Oral 20 mg Tablet Dose may be increased gradually to a maximum of 50 mg daily.
6 Social anxiety disorder Oral 20 mg Tablet Given daily. Dose may be increased if necessary, to a maximum of 50 or 60 mg daily.
7 Premenstrual dysphoric disorder Oral 12.5 mg Controlled-release tablets o.d. Dose usually in the morning, which may be increased to 25 mg once daily, if necessary, after an interval of at least one week. Treatment may be given throughout the menstrual cycle or limited to the luteal phase.
8 Moderate to severe vasomotor symptoms associated with menopause In this case paroxetine is given as the mesilate. The usual dose is the equivalent of paroxetine 7.5 mg o.d given at bed time.

Ref :-  Book : Martindale    Page : 441   Edition : 38  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :    Page :    Edition :   
Precaution :- If a Patient is using 'paroxetine' drug in  Depressive disorder  disease, then Please Contraindication : in pregnancy .

►  Side Effect : Sexual dysfunction, Constipation, Vasospasm, Sweating, Somnolence, Anxiety, Serious adverse effects are, Serotonin syndrome from concomitant administration of MAOI characterised by , Hyperthermia, Muscle rigidity, Myoclonus, And rapid fluctuations in mental status and vital signs, May precipitate mania in a bipolar patient
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 221   Edition : 3.  

►  Drug Interaction : Drug interaction of paroxetine is with Monoamine Oxidase Inhibitors, , , ,  Pimozide , Thioridazine
Ref :-   Book : Martindale    Page : 424,441   Edition : 38.  

  ►    Mechanism of Drug Drug Interaction :  SSRIs interact with other drugs mainly as a result of their inhibitory activity on hepatic cytochrome P450 isoenzymes. Individual SSRIs do not all exhibit the same degree of inhibition nor do they react with the same isoenzymes. The drugs inhibited by specific SSRIs depends on the isoenzyme affected. As SSRIs have occasionally been associated with bleeding disorders and other effects on the blood, caution is advised when they are given with drugs known to affect platelet function. Although different antidepressants have been used together under expert supervision in refractory cases of depression, severe adverse reactions including the serotonin syndrome may occur. Sequential prescribing of different types of antidepressant may also produce adverse reactions, and an appropriate drugfree interval should elapse between stopping one type of antidepressant and starting another. SSRIs should not generally be given to patients receiving MAOIs or for at least 2 weeks after their use. No treatment-free period is necessary after stopping a reversible inhibitor of monoamine oxidase type A (RIMA) and starting an SSRI. At least one week should elapse between withdrawing an SSRI and starting any drug liable to provoke a serious reaction (e.g. phenelzine); in the case of the SSRI sertraline the drug-free interval is extended to 2 weeks, and for fluoxetine 5 weeks, because of their longer half-lives. (For fluoxetine, the interval may need to be further extended if therapy has been prolonged or if high doses have been given.) Adverse effects such as the serotonin syndrome may also occur when the SSRIs are given with other drugs known to act on the same neurotransmitter, a consequence of synergistic interaction.
Ref :-   Book : Martindale    Page : 424,441   Edition : 38.  

►  Contraindication : Treatment should be stopped if seizures develop or when there is an increase in seizure frequency, Drug should be stopped in patients who develop a rash, If affected, patients should not drive or operate machinery
Ref :-   Book : Martindale    Page : 422,441   Edition : 38.  
  ►  Mechanism of Action :   The selective serotonin reuptake inhibitors (SSRIs) represent a chemically diverse class of agents that have as their primary action the inhibition of the serotonin transporter (SERT).
Ref :-   Book : Basic & Clinical pharmacology    Page : 525   Edition : 12.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- Belladonna with Another pathway.  

  ►  Pathway with its reference as follows :-
  • Increasing anticholinergic activity of tricyclic antidepressants . --- (: Duke, J. (2002). Handbook of Medicinal Herbs (2nd ed.). Boca Raton London New York Washington ,D.C. )

  •   ►  URL --
  • .

  • DIETARY Substance Interactions

    ​   ► This Medicine interact with :- NA

    ContraIndication DIETARY Substance

    ​   ► This Medicine contraindicate with :- BELLABONNA with Increasing anticholinergic activity of tricyclic antidepressants ..   BELLABONNA with It increased the side effect of drug ..   EPIMEDIUM I.E. EPIMEDIUM BREVICORNU with inhibit CYP2D6.   GINKGO BILOBA with Experienced sexual dysfunction , addition of ginkgo biloba extract ..  

      ►  Reference :-
  • Duke, J. (2002). Handbook of Medicinal Herbs (2nd ed.). Boca Raton London New York Washington ,D.C.
  • Gaby, A. (2006). A–Z Guide to Drug-Herb-Vitamin Interactions. 2nd ed. New York: Three Rivers Press
  • Williamson, E. (2009). Stockley's Herbal Medicines Interaction .. London: Pharmacutical press.

  •   ►  URL --

    ►   Route of Elimination :   NA

    ►    Plasma Half-life :   Min value :-   about 21 hours,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 441   Edition : 38.  

    ►    Peak Plasma Concentration :   Min value :-   Occur within 5 hours of ingestion,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 441   Edition : 38.